Crossmark

Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa

Crossref DOI link: https://doi.org/10.1186/s12918-018-0587-5

Published Online: 2018-06-11

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fang, Xin

Monk, Jonathan M.

Mih, Nathan

Du, Bin

Sastry, Anand V.

Kavvas, Erol

Seif, Yara

Smarr, Larry

Palsson, Bernhard O. https://orcid.org/0000-0002-9403-509X
Funding

Funding for this research was provided by:

UC San Diego Center for Microbiome Innovation (Microbial Science Initiative Graduate Research Fellowship)

National Institutes of Health (1-U01-AI124316-01)

Novo Nordisk (NNF10CC1016517)
License Information

Text and Data Mining valid from 2018-06-11

Version of Record valid from 2018-06-11
More Information

Article History

Received: 12 March 2018

Accepted: 21 May 2018

First Online: 11 June 2018

Ethics approval and consent to participate

: Not Applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below